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Background/objective: Patients with advanced ovarian cancer should be treated by radical
debulking surgery aiming at complete tumor resection. Unfortunately, approximately 70% of
patients present with advanced disease, when optimal debulking cannot be obtained, and,
therefore, these patients gain little benefit from surgery. Neoadjuvant chemotherapy (NAC)
followed by interval debulking surgery has been proposed as a novel therapeutic approach in
such cases.
Methods: A prospective randomized controlled study was conducted on 30 women selected
from patients attending the gynecologic clinic of El-Shatby Maternity University Hospital,
Alexandria, Egypt. Cases were randomly divided into two groups. Group I included 15 women
who were undergoing upfront surgery, followed by adjuvant chemotherapy. Group II included
15 women subjected to NAC, followed by interval debulking surgery.
Results: We found that optimal cytoreduction was higher in the first group (86.7%) compared
with the upfront surgery group (6.7%). Additionally, we also observed that surgical aggressive-
ness (blood-loss rates, bladder injury, gynecologic impedance tomograph intervention) and
postoperative morbidity (intensive care unit admission, sepsis, duration of hospital stay) were
both significantly lower in the first group relative to the upfront-surgery group.pt.
s upfront
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surgery followed by chemotherapy inConclusion: This study found that interval debulking surgery is a better option relative to
upfront surgery based on intra- and postoperative morbidity, provided that optimal debulking
of all tumor tissue is achieved during that surgery.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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146Introduction
Ovarian cancer is the leading cause of death among all gyne-
cological malignancies in developed countries [1]. The inci-
dence of ovarian cancer is up to 10-times higher in Western
countries than in rural Asian and African countries [2].
Surgery plays a major role in the management of almost
all cases of ovarian malignancies. Adjuvant chemotherapy
following surgery or its neoadjuvant form makes the man-
agement of ovarian carcinoma complete [3].
Primary surgery is the mainstay of treatment for ovarian
cancer, followed by adjuvant chemotherapy to destroy any
gross or microscopic residual tumor cells [3]. Interval
debulking surgery (IDS) is an operation performed in
patients, after a short course of induction chemotherapy
to remove as much primary and metastatic disease as possi-
ble, to facilitate response to subsequent chemotherapy and
improve patient survival [4–6]. The term neoadjuvant
chemotherapy (NAC) is more specific, in that it describes
the administration of chemotherapy when primary debulk-
ing surgery is not feasible. It is usually performed after
two to four cycles of chemotherapy. Many authors reported
rates of optimal resection in IDS after induction chemother-
apy ranging from 77% to 94% [6–8]. Patients with advanced
ovarian cancer should be treated by radical debulking sur-
gery aiming at complete tumor resection. Unfortunately,
approximately 70% of patients present with advanced dis-
ease, when optimal debulking cannot be obtained, and,
therefore, these patients gain little benefit from surgery.
NAC, followed by IDS, has been proposed as a novel thera-
peutic approach in such cases.
Materials and methods
This prospective randomized controlled trial included a
total of 30 patients with Stage III epithelial ovarian carci-
noma that was evaluated between 2011 and 2013. Patients
who were selected for our study had advanced ovarian car-
cinoma and were free from severe concomitant medical ill-
ness that could preclude surgical interference. Patients
were subjected to physical examination, serum level of CA
125 measurement, radiological studies, and histopathologi-
cal confirmation of ovarian carcinoma. The patients were
randomized into two groups by the closed-envelope
method. Group I consisted of 15 patients who underwent
upfront surgery, followed by six cycles of chemotherapy
(platin and taxol). Group II consisted of 15 patients, who
received three cycles of chemotherapy (platin and taxol),
followed by interval debulking surgery, and then received
another three cycles of chemotherapy (platin and taxol).
The surgery was performed by experienced gynecological
oncology surgeons, with total hysterectomy with bilateralis MH, Elagwany AMS, Adjuvant
advanced epithelial ovarian carcisalpingo-oophorectomy, omentectomy, excision of malig-
nant masses, and lymphadenectomy. Both groups were
compared for debulking rate (optimum and suboptimum),
duration of surgery, amount of blood loss during surgery
by weighted methods (weight and number of operative tow-
els during surgery), intra- and postoperative morbidity and
mortality, and duration of hospital stay after surgery.
Results
Table 1 compares debulking rates between the two studied
groups according to surgical intervention. In Group I, most
cases (93.3%) undergoing surgical intervention had subopti-
mal de-bulking, while in Group II, most of the cases (86.7%)
had optimal debulking after surgery. The rate in Group II
was higher compared with that found in the literature
(50%). This could be attributed to many peritoneal implants
and adhesions related to the advanced stage of cancer.
Also, this may be related to our small sample size.
Comparing the two groups revealed that there was a sig-
nificant increase in debulking rates and a significant
decrease in duration of surgery and amount of blood loss
during the operation among cases in Group II. Table 2 com-
pares the two groups according to intra- and postoperative
morbidity. In Group I, 13.3% of cases had bladder injury dur-
ing surgery compared with 6.7% in Group II. In Group I,
26.7% of cases had gynecologic impedance tomograph
(GIT) intervention (injury or resection), whereas in Group
II, 13.3% of cases had GIT intervention. In Group I, 40% of
cases received blood transfusions compared with 20% in
Group II. In Group I, 33.3% of cases were admitted to the
intensive care unit (ICU) postoperation compared with
6.7% of Group II cases. In Group I, 20.0% of cases experi-
enced postoperative sepsis compared with 13.3% of cases
in Group II. There were no significant differences observed
between any of the previous factors.
In Group I, all cases stayed in hospital postoperation
>3 days, whereas in Group II, 86.7% of cases stayed in hospi-
tal postoperation <3 days and 13.3% of cases stayed >3 days.
There was a significant decrease in duration of postopera-
tive hospital stay in Group II cases. Those in Group II were
discharged home at Days 2 or 3, given that less-invasive
surgery was required due to the preoperative chemotherapy
treatment that lowered the cancer mass, accompanied by
rapid recovery. Patients were discharged home at Day 3,
after assessing the wound and excluding burst abdomen or
wound infection, and instructed to receive wound care
and dressing daily. Patients were followed up at the hospital
once weekly until removal of stitches.
Table 3 compares the two studied groups according to
performance status after surgical interference. Our results
indicated that most of the patients in Group I had Easternchemotherapy followed by interval debulking surgery versus upfront
noma ..., Hematol Oncol Stem Cell Ther (2016), http://dx.doi.org/
Table 1 Comparison between the two studied groups according to surgical interference.
Surgery Groups Total
Group I Group II
No. % No. % No. %
Debulking rate
Optimum 1 6.7 13 86.7 14 46.7
Suboptimum 14 93.3 2 13.3 16 53.3
FEp <0.001*
Duration of surgery (mean)
<2 h 3 20.0 14 93.3 17 56.7
>2 h 12 80.0 1 6.7 13 43.3
v2p <0.001*
Blood loss
<1 L 4 26.7 12 80.0 16 53.3
>1 L 11 73.3 3 20.0 14 46.7
v2p 0.003*
Note. FE = .
* Denotes statistical significance according to chi-square analysis.
Table 2 Comparison between the two studied groups according to operative and postoperative morbidity.
Morbidity Groups Total
Group I Group II
No. % No. % No. %
Intraoperative Bladder injury
No 11 73.3 14 93.3 25 83.3
Yes 4 13.3 1 6.7 5 16.6
FEp 1.000
GIT intervention
No 11 73.3 13 86.7 24 80.0
Yes 4 26.7 2 13.3 6 20.0
FEp 0.651
Blood transfusion
No 9 60.0 12 80.0 21 70.0
Yes 6 40.0 3 20.0 9 30.0
FEp 0.427
Postoperative ICU admission
No 10 66.7 14 93.3 24 80
Yes 5 33.3 1 6.7 6 20
FEp 0.169
Sepsis
No 10 80.0 13 86.7 23 76.6
Yes 5 20.0 2 13.3 7 23.3
FEp 1.000
Hospital stay
<3 d 0 0.0 13 86.7 13 43.3
>3 d 15 100.0 2 13.3 17 56.7
v2p <0.001*
Note. FE = ; GIT = gynecologic impedance tomograph; ICU = intensive care unit.
* Denotes statistical significance according to chi-square analysis.
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19 March 2016Cooperative Oncology Group (ECOG) performance status 2
(53.3%), whereas most patients in Group II had ECOG perfor-
mance status 1 (53.3%). There difference in ECOG status
between the groups was significant.
Discussion
The clinical basis of aggressive cytoreductive surgery in the
initial management of ovarian cancer is significantly
improved survival rates gained by those patients in whom
optimal cytoreductive surgery was accomplished. The pres-
ence of residual disease after surgery is one of the most
adverse prognostic factors for survival. Therefore, although
the definition of optimal cytoreduction has been modified
over the past 2 decades, it is generally agreed that every
attempt should be made to surgically resect as much disease
as is safely possible [9,10].
Recently, several investigators introduced the concept of
IDS, describing a surgical procedure following NAC to
achieve a maximum debulking rate of tumor tissue
[11,12]. Our study showed that most cases receiving NAC,
followed by interval debulking surgery, experienced opti-
mum debulking of tumor tissue, whereas most cases under-
going upfront surgery experienced suboptimal debulking of
the tumor tissue.
Most of the available research on this issue reported
results similar to ours regarding the debulking rate. Mazzeo
et al. [13] found that for most patients in whom cytoreduc-
tion had been performed, a complete macroscopic surgical
resection could be achieved. Hegazy et al. [14] found that
optimal cytoreduction was higher in the NAC group (72.2%)
compared with the group receiving upfront surgery
(62.4%). Zheng et al. [15] found that the optimal debulking
rate was 60% in the NAC/IDS group, which was significantly
higher than that observed in the primary debulking surgery
group (32.4%). In our study, we found that IDS was shorter
in duration than upfront surgery at <2 h, and that 93.3% of
patients who had undergone IDS had their subsequent sur-
gery competed in <2 h. By contrast, only 20% of patients
who had undergone upfront surgery had their surgery com-
pleted in <2 h. Mazzeo et al. [13] found that the duration
of IDS was <2 h, similar to our findings.
Regarding the amount of blood loss during operation, we
found that most patients lost <1 L of blood during IDS,
whereas most patients lost >1 L of blood during upfront sur-
gery. Many studies showed results similar to ours regarding
blood loss. Hegazy et al. [14] found that blood loss rates
were significantly lower in the NAC group relative to the
conventional group, similar to our findings. Additionally,Table 3 Comparison between the two studied groups according
Group I (n = 15)
No. %
Performance status
0 1 6.7
1 6 40.0
2 8 53.3
* Statistical significance based on Monte Carlo test for comparing be
Please cite this article in press as: Melis MH, Elagwany AMS, Adjuvant
surgery followed by chemotherapy in advanced epithelial ovarian carciZheng et al. [15] found that the NAC/IDS group had signifi-
cantly less intraoperative estimated blood loss and
transfusion.
Most of the patients in our study who had undergone IDS
stayed in the hospital postoperation <3 days, whereas all
patients who had undergone upfront surgery stayed >3 days.
Similarly, Hegazy et al. [14] found that total hospital stay
was significantly lower in the NAC group relative to the con-
ventional group.
We also found that intraoperative morbidity was
improved following IDS compared with upfront surgery.
The rate of bladder injury during IDS was 6.7% compared
with 13.3% in upfront surgery. Additionally, GIT intervention
was required less during IDS (13.3%) compared with 26.7% in
upfront surgery. Mazzeo et al. [13] reported similar results,
finding that no major complications were recorded during
IDS. Furthermore, Kuhn et al. [6] found that there was no
difference in intraoperative morbidity and complication
rates between NAC and primary surgery, which was a differ-
ent finding from our results.
Postoperative morbidity in the current study was better
in all patients who had undergone IDS relative to upfront
surgery. We found that the number of cases of postopera-
tive sepsis was decreased in IDS patients (13.3%) compared
with 20% of upfront surgery cases. Additionally, the rate of
postoperative ICU admission was less in IDS cases compared
with upfront surgery cases. Many studies reported similar
results, including Hegazy et al. [14] who reported that
parameters of surgical aggressiveness (blood-loss rates,
ICU stay, and total hospital stay) were significantly lower
in the NAC group relative to the conventional group. Kang
et al. [16] found that postoperative rates of adverse effects
and mortality tended to be higher after primary debulking
than after IDS. The hazard ratio for death in the group
assigned to NAC, followed by IDS, compared with the group
assigned to primary debulking surgery followed by
chemotherapy was 0.98, and the hazard ratio for progres-
sive disease was 1.01. Morice et al. [17] found that the rates
of postoperative morbidity, blood transfusion, and median
length of hospitalization were significantly reduced in the
IDS group.
We also observed that most patients in our study in
Group II had ECOG performance status 1, while most
patients in Group I had performance status 2. There were
no previous studies regarding the performance status of
ovarian carcinoma patients relative to IDS.
In contrast to our study, Ma et al. [18] found that intra-
operative injury rates were similar between IDS and upfront
surgery, and mild perioperative complication rates wereto performance status.
Group II (n = 15) p*
No. %
2 13.3 0.075
8 53.3
5 33.3
tween the studied groups.
chemotherapy followed by interval debulking surgery versus upfront
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19 March 2016also similar. Sehouli et al. [19] found that upfront surgery
had a more favorable outcome than IDS in both overall sur-
vival and progression-free survival in advanced ovarian car-
cinoma patients. Also, Kuhn et al. [6] found that there was
no difference in postoperative complication rates between
NAC and primary surgery groups.
Conclusion
The most common management of advanced stages of
epithelial ovarian carcinoma is upfront surgery, followed
by adjuvant chemotherapy. We compared the efficacy of
this management with an alternative line of management,
NAC (three cycles), followed by IDS. Our results indicated
that IDS is better than upfront surgery in the areas of
intra- and postoperative morbidity, provided that optimal
debulking of all tumor tissue during surgery occurs.
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